moderate Plaque psoriasis (DBCOND0020390)

Identifiers

Synonyms

Moderate Plaque Psoriasis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bimekizumab	An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.	Interleukin-17Atarget Interleukin-17Ftarget
Brodalumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.	No drug targets
Clobetasol propionate	A corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis.	Glucocorticoid receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Annexin A1target Mineralocorticoid receptortarget Corticosteroid-binding globulincarrier Albumincarrier
Deucravacitinib	A TYK2 inhibitor being investigated as a treatment for psoriasis.	Non-receptor tyrosine-protein kinase TYK2target Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2D6enzyme Cocaine esteraseenzyme UDP-glucuronosyltransferase 1A9enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 1transporter Solute carrier organic anion transporter family member 1B3transporter
Etanercept	A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.	Tumor necrosis factortarget Lymphotoxin-alphatarget Low affinity immunoglobulin gamma Fc region receptor III-Btarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget Low affinity immunoglobulin gamma Fc region receptor II-atarget Low affinity immunoglobulin gamma Fc region receptor II-btarget Low affinity immunoglobulin gamma Fc region receptor II-ctarget Complement component 1q (C1q)target
Guselkumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.	Interleukin-23 subunit alphatarget
Secukinumab	An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.	Interleukin-17Atarget
Ustekinumab	A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.	Interleukin-12 subunit betatarget Interleukin-23target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06333860	A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)	Deucravacitinib Risankizumab	treatment	4	recruiting
NCT06039189	Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis	Guselkumab	treatment	3	active_not_recruiting
NCT06247319	Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece	No drug interventions	Not Available	Not Available	recruiting
NCT03059953	A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)	No drug interventions	Not Available	Not Available	completed